The historical rank and industry rank for Burning Rock Biotech's ROE % or its related term are showing as below:
FRA:6BU0'
s ROE % Range Over the Past 10 Years
Min: -66.88 Med: -51.02 Max: -10.09
Current: -10.92
During the past 9 years, Burning Rock Biotech's highest ROE % was -10.09%. The lowest was -66.88%. And the median was -51.02%.
FRA:6BU0's ROE % is ranked worse than 61.88% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.31
vs FRA:6BU0: -10.92
Burning Rock Biotech (FRA:6BU0) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Burning Rock Biotech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's ROE % distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Burning Rock Biotech (FRA:6BU0) has a ROE % of -13.52% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Burning Rock Biotech and its competitors. According to the industry distribution chart, Burning Rock Biotech ranks #125 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 61.9%.
Is Burning Rock Biotech's ROE % too high?
Burning Rock Biotech's current ROE % is -13.52%. Based on the distribution chart, Burning Rock Biotech ranks #125 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Burning Rock Biotech has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's ROE % compare to XGN and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #125 out of 202 companies for ROE %. This places Burning Rock Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current ROE % is -13.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Fairly Valued. The stock's GF Value™ is €5.43, compared to a current price of €6.00 — trading 10.5% above its estimated fair value. The current ROE % is -13.52%. Burning Rock Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current ROE % is -13.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of €6.00 is trading 10.5% above its estimated GF Value™ of €5.43.
GuruFocus considers Burning Rock Biotech to be Fairly Valued.
Key valuation signals for FRA:6BU0:
ROE %: -13.52%
GF Value™: €5.43 vs. price of €6.00 (10.5% above fair value)
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
59GF Score
Get the complete analysis for FRA:6BU0
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 
